Titan Pharmaceuticals, Inc.

280 articles about Titan Pharmaceuticals, Inc.

• Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock

  9/18/2023

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that it has entered into a definitive securities purchase agreement (the “Purchase Agreement”) with The Sire Group Ltd.

• Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets

  7/27/2023

  Titan Pharmaceuticals, Inc. announced that it has entered into an Asset Purchase Agreement with Fedson, Inc., a Delaware Corporation, for the sale of certain ProNeura assets including Titan’s portfolio of drug addiction products, in addition to other early development programs based on the ProNeura drug delivery technology.

• Titan Pharmaceuticals Provides Shareholder Update

  12/15/2022

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") is pleased to report that it has entered a non-binding letter of intent to complete a reverse merger with a leading developer in Advanced Air Mobility (AAM) (the “Proposed Reverse Merger”).

• UPDATE -- Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.

  12/12/2022

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has granted an exclusive license to Ocular Therapeutix Inc. (“Ocular”) pertaining to certain patent applications for ophthalmic uses in both humans and nonhuman animals in the territory of the United States.

• Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.

  12/12/2022

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has granted an exclusive license to Ocular Therapeutix Inc. (“Ocular”) pertaining to certain patent applications for ophthalmic uses in both humans and nonhuman animals in the territory of the United States.

• Titan Pharmaceuticals Announces Board Expansion and Management Changes

  8/16/2022

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has expanded its Board of Directors (the "Board") from five (5) to eleven (11) and appointed six new directors following their election at its special meeting of stockholders held on August 15, 2022.

• Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant

  7/5/2022

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application for a Phase 1 study of its six-month or longer subdermal formulation of nalmefene.

• Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-Market

  2/2/2022

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,374,242 shares of its common stock.

• Titan Pharmaceuticals to Explore Strategic Alternatives

  12/21/2021

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value.

• Sustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021

  11/8/2021

  Titan Pharmaceuticals, Inc. announced that, in a presentation given at the Society for Neuroscience 2021 Meeting, Ben Land, Ph.D., Research Assistant Professor at the University of Washington's Department of Pharmacology, reported additional positive data from an ongoing in vivo study of its human kappa-opioid receptor agonist ProNeura®-based implant in an established 5'-guanidinonaltrindole itch-induced mouse model.

• Titan Announces Upcoming TP-2021 Implant Data Presentation at Neuroscience 2021

  11/5/2021

  Titan Pharmaceuticals, Inc. announced that data from continuing studies of its ProNeura ® -based TP-2021 implant in an established animal model of chronic pruritus will be presented at the Society for Neuroscience 2021 Meeting, being held virtually, on November 8 .  

• Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries

  10/25/2021

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has received funding from the Bill & Melinda Gates Foundation to support the demonstration of its ability to deliver a human immunodeficiency virus ("HIV") preventative therapeutic

• Titan Pharmaceuticals and MUSC FRD Enter Into Research and Option License Agreement

  10/12/2021

  Titan to Evaluate and Potentially Licence Tetrapeptide Kappa-Opioid Agonist Compounds for use in Combination with its ProNeura® Technology Platform -

• Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus

  6/23/2021

   Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist has demonstrated the potential to provide extended efficacy.

• Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program

  2/1/2021

   Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potency and specificity for the human kappa-opioid receptor ("KOR").

• Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering

  1/15/2021

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $9.7 million of its common stock in a registered direct offering and warrants to purchase common stock in a concurrent private placement

• Titan Pharmaceuticals Announces Reverse Stock Split - Nov 30, 2020

  11/30/2020

  Titan Pharmaceuticals, Inc. announced that its Board of Directors has approved a 1-for-30 reverse stock split of the Company's common stock, which will be effective at 5:00 p.m. Eastern Time on Monday, November 30, 2020.

• Titan Pharmaceuticals Reports Third Quarter 2020 Financial Results

  11/16/2020

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the third quarter ended September 30, 2020 and provided an update on its business.

• Titan Pharmaceuticals Completes Debt Settlement With Molteni And Horizon & Acquisiton Of JT Pharma's Kappa Opioid Agonist Peptide, JT-09

  11/2/2020

  Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced the completion of its agreement to settle all of its debt obligations with Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A ("Molteni") and Horizon Credit LLC II ("Horizon"), as well as its agreement to acquire JT Pharmaceuticals, Inc.'s  ("JT Pharma") kappa opioid agonist peptide, JT-09, for use in combination with Titan's ProNeura® long-term,

• Titan Pharmaceuticals Enters Into Definitive Agreement To Acquire JT Pharma's Kappa Opioid Agonist Peptide, JT-09

  10/28/2020

  - Titan today announced that it has entered into a definitive asset purchase agreement (the "Agreement") with JT Pharmaceuticals, Inc.